ひとことで言うと
bluebird bio developed approved gene therapies for beta thalassemia, sickle cell disease and a rare brain disorder, using viruses to add working genes rather than editing existing ones. Its scientific record is strong and its commercial history difficult: extremely expensive one-time treatments for small populations turned out to be a hard business, and the company withdrew from the European market and was eventually taken private.
bluebird bio developed lentiviral gene-addition therapies including Zynteglo (beta thalassemia), Lyfgenia (sickle cell disease) and Skysona (cerebral adrenoleukodystrophy). Despite approvals, commercial difficulties led to withdrawal from the European market and, in 2025, acquisition and take-private. Its history is the field's clearest illustration that regulatory success and commercial viability are separate problems.
Sources
- U.S. Food and Drug Administration
Approved cellular and gene therapy products ↗